The DOI matches its Crossref record.
New hepatitis B vaccine formulated with an improved adjuvant system
Abstract
A new hepatitis B vaccine (FENDrix, GlaxoSmithKline Biologicals) containing as active substance 20 microg of recombinant hepatitis B virus surface antigen produced in Saccharomyces cerevisiae has recently been licensed in Europe. It is prepared with a novel adjuvant system: aluminum phosphate and 3-O-desacyl-4 -monophosphoryl lipid A. It is intended for use in adults from the age of 15 years onwards for active immunization against hepatitis B virus infection for patients with renal insufficiency (including prehemodialysis and hemodialysis patients). It is applied in a four-dose scheme: day 0, month 1, 2 and 6 after day 0. Due to the improved adjuvant system it induces higher antibody concentrations that reach protective levels in a faster fashion. Furthermore, due to higher titers reached after the primary immunization course, protective levels are retained for a longer period of time. Vaccination with FENDrix induces more transient local symptoms, with pain at the injection site being the most frequently reported solicited local symptom. Other symptoms such as fatigue, gastrointestinal disorders and headaches were also frequently observed but resolved without sequelae. The higher risk of hepatitis B transmission in patients with end-stage renal disease and the often immunocompromised status of these patients afford a tailored vaccination strategy that, up to now, has consisted of injecting double doses of ordinary hepatitis B vaccines. With the introduction of FENDrix there now exists an efficient alternative with superior immunogenicity that is, despite comparatively higher reactogenicity, well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Pasquale, A., Preiss, S., Silva, F., & Garçon, N. (2015) · Vaccines · doi:10.3390/vaccines3020320 · Cited by 648
Steinhagen, F., Kinjo, T., Bode, C., & Klinman, D. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.08.002 · Cited by 501
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Metadata
- Authors
- Kundi, M.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2007-04
- Volume
- 6
- Issue
- 2
- Pages
- 133-140
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2143895770
- Cited by
- 193
- References
- 0
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New hepatitis B vaccine formulated with an improved adjuvant system. https://app.cochat.ai/papers/10.1586/14760584.6.2.133
- The paper
- Kundi, M. (2007). New hepatitis B vaccine formulated with an improved adjuvant system. Expert Review of Vaccines. https://doi.org/10.1586/14760584.6.2.133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.